Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Tue, 30.04.2024
Evotec SE
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASES
STRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING FOR IDENTIFICATION OF NOVEL TARGETS
JOINT EFFORT AIMS TO DEVELOP INNOVATIVE THERAPIES IN PRECISION CARDIOLOGY
Berlin and Hamburg, Germany, 30 April 2024:
Bayer and the German-based l [ … ]
Wed, 24.04.2024
Evotec SE
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE
PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M
EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST – EVOTEC BIOLOGICS” STARTING Q1 2024
Hamburg, Germany, 24 April 202 [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in [ … ]
Wed, 17.04.2024
Evotec SE
Hamburg, Germany, 17 April 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s Management Board, bringing with her a wealth of experience and experti [ … ]
Wed, 06.03.2024
Evotec SE
CLARIS’S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC’S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES
AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS’S PORTFOLIO COMPANY IAMA
Hamburg, Germany, and Turin, Italy, 06 March 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, [ … ]
Wed, 07.02.2024
Evotec SE
JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV
AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV
Hamburg, Germany, 07 February 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; [ … ]
Mon, 22.01.2024
Evotec SE
Hamburg, Germany, 22 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari [ … ]
Wed, 10.01.2024
Evotec SE
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”)
THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR [ … ]
Mon, 08.01.2024
Evotec SE
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH
Hamburg, Germany, 08 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer [ … ]
Thu, 04.01.2024
Evotec SE
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM
A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC
AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC
Hamburg, Germany, and Paris, France, 04 Janu [ … ]